Zai Lab to Present New Oncology Research at 2022 AACR Annual Meeting

-  First preview of preclinical data for ZL-1218, an anti-CCR8 antibody, in an oral presentation

-  Poster presentations will feature three additional candidates of Zai Lab’s internal immuno-oncology/oncology pipeline: ZL-1201 (anti-CD47 antibody) for advanced hematologic malignancies and solid tumors, ZL-1211 (anti-CLDN18.2 antibody) for gastric and pancreatic cancer and ZL-2201 (DNA-PK inhibitor) for solid tumors

-  Abstracts: Oral presentation 3590; poster presentations: 3425, 5234 and 2594

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, will present new data from its internal oncology discovery portfolio at the upcoming 2022 American Association for Cancer Research (AACR) Annual Meeting in New Orleans on April 8-13, 2022. Key early-stage discovery programs will be featured in these presentations, including ZL-1218, a novel anti-CCR8 antibody for solid tumors; ZL-1201, a CD47-targeting antibody for advanced hematologic malignancies and solid tumors; ZL-1211, a Claudin18.2-specific antibody for gastric and pancreatic cancer; and ZL-2201, a highly selective small-molecule DNA-PK inhibitor for anti-cancer therapy.

For the first time, Zai Lab will present data on ZL-1218, a novel antibody that targets the CCR8 receptor selectively expressed on resident regulatory T-cells (Tregs) in solid tumors. This oral presentation will highlight the discovery and development of this therapeutic, including the antitumor activity of ZL-1218 in an animal model, as a single agent and in combination with anti-PD-1. This presentation provides preclinical data supporting ZL-1218 as a potential clinical therapeutic candidate for solid tumors.

Three poster presentations will highlight additional key programs in Zai Lab’s internal oncology pipeline. One presentation will focus on ZL-1201, a differentiated anti-CD47 monoclonal antibody which is currently being studied in Phase I (NCT042576617). Preclinical data will measure the enhanced antitumor effect by combining ZL-1201 with the current standard of care antibody treatments in hematologic and solid tumor models. Data from ZL-1211, a CLDN18.2-specific monoclonal antibody will be presented with preclinical results supporting effective targeting of CLDN18.2+ gastric cancer, including CLDN18.2-low expressing malignancies. (ZL-1211 is currently in Phase I trials NCT05065710). Another presentation will feature the discovery and development of ZL-2201, a novel, orally bioavailable, selective DNA-PK inhibitor.

“We are proud to present data from our growing internal Oncology pipeline at AACR, demonstrating the progress of Zai Lab’s oncology research portfolio,” said Alan Sandler, M.D., President and Head of Global Development, Oncology, Zai Lab. “Our growing discovery programs are an important part of our deep and diversified oncology portfolio that spans from discovery to commercialization. We remain focused on advancing our research to address the urgent need for effective treatment options in cancer care for patients in China and around the world.”

Details regarding presentations about Zai Lab research at AACR 2022 are listed below:

Oral presentation:

Title: ZL-1218, a novel anti-CCR8 antibody, exerts potent antitumor effect by depleting intratumoral regulatory T cells Abstract number: 3590 Session title: Promising New Therapies Date and time: Tuesday, April 12, 2022, 2:50 PM - 3:05 PM ET Location: La Nouvelle Orleans C, Convention Center Presenter: David Bellovin, PhD, Senior Director, Head of Biology, Oncology Discovery, Zai Lab

Poster presentations:

Title: The CD47-targeting antibody ZL-1201 enhances anti-tumor activity of standard of care therapeutic antibodies by promoting phagocytosis in hematologic and solid tumor models Abstract number: 3425 Date and Time: Tuesday, April 12, 2022, 1:30 PM - 5:00 PM ET Location: Exhibit Halls D-H, Poster Section 32 Title: ZL-1211 exhibits robust anti-tumor activity by enhancing ADCC and activating innate and adaptive immunity in CLDN18.2-high and -low expressing gastric cancer models Abstract number: 5234 Date and time: Sunday, April 10, 2022, 1:30 PM - 5:00 PM ET Location: Exhibit Halls D-H, Poster Section 39 Title: Discovery and characterization of ZL-2201, a potent, highly-selective, and orally bioavailable small-molecule DNA-PK inhibitor Abstract number: 2594 Date and time: Tuesday, April 12, 2022, 9:00 AM - 12:30 PM ET Location: Exhibit Halls D-H, Poster Section 22

About Zai Lab

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is a patient-focused, innovative, commercial-stage, global biopharmaceutical company focused on developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. To that end, our experienced team has secured partnerships with leading global biopharmaceutical companies in order to generate a broad pipeline of innovative marketed products and product candidates. We have also built an in-house team with strong product discovery and translational research capabilities and are establishing a pipeline of proprietary product candidates with global rights. Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing, and commercializing our portfolio in order to impact human health worldwide.

For additional information about the Company, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.

Zai Lab Forward-Looking Statements

This press release contains forward-looking statements about clinical trials, data readouts and presentations, our clinical development programs, including our research and development program for the treatment of ovarian cancer in China; the potential of our commercial business and pipeline programs, and the risk and uncertainties associated with drug development and commercialization. These forward-looking statements include, without limitation, statements containing words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “will,” “would” and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact nor are they guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products; (2) our ability to finance our operations and business initiatives and obtain funding for such activities, (3) our results of clinical and pre-clinical development of our product candidates, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates, (5) the effects of the novel coronavirus (COVID-19) pandemic on our business and general economic, regulatory and political conditions and (6) the risk factors identified in our most recent annual or quarterly report and in other reports we have filed with the U.S. Securities and Exchange Commission. We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

More information about Zai Laboratory and its filings can be found on the SEC.gov website.

For more information, please contact:

Media: Jennifer Chang / Xiaoyu Chen
+1 (917) 446 3140 / +86 185 0015 5011
jennifer.chang@zailaboratory.com / xiaoyu.chen@zailaboratory.com

Investor Relations: Ron Aldridge / Lina Zhang
+1 (781) 434-8465 / +86 136 8257 6943
ronald.aldridge@zailaboratory.com / lina.zhang@zailaboratory.com